303 related articles for article (PubMed ID: 12542895)
1. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
McDowell A; Young IS; Wisdom GB
J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
[TBL] [Abstract][Full Text] [Related]
2. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
Turk Z; Mrzljak V; Turk N; Metelko Z
Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563
[TBL] [Abstract][Full Text] [Related]
3. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to oxidized low density lipoprotein in relation with coronary artery disease.
Soto Y; Conde H; Aroche R; Brito V; Luaces P; Nasiff A; Obregón A; Vázquez López AM
Hum Antibodies; 2009; 18(3):109-17. PubMed ID: 19729805
[TBL] [Abstract][Full Text] [Related]
5. Relationships between serum levels of autoantibodies against oxidized low density lipoproteins, lipid-soluble antioxidants and apolipoprotein B in patients with coronary heart disease.
Bakalova RA; Hadzhimitova V; Ribarov S
Gen Physiol Biophys; 2000 Mar; 19(1):103-13. PubMed ID: 10930142
[TBL] [Abstract][Full Text] [Related]
6. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
7. Significantly higher levels of oxidized LDL autoantibody in coronary artery disease patients.
Liang KW; Huang JL; Kao CH; Hsueh CW; Ho HY; Lee WL; Wang KY; Huang DS; Chen YT; Ting CT
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):101-6. PubMed ID: 10677919
[TBL] [Abstract][Full Text] [Related]
8. Auto antibodies against oxidized low density lipoprotein in severe preeclampsia.
Jain M; Sawhney H; Aggarwal N; Vashistha K; Majumdhar S
J Obstet Gynaecol Res; 2004 Jun; 30(3):188-92. PubMed ID: 15210040
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls.
van de Vijver LP; Steyger R; van Poppel G; Boer JM; Kruijssen DA; Seidell JC; Princen HM
Atherosclerosis; 1996 May; 122(2):245-53. PubMed ID: 8769687
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect.
Johnston TP; Zhou X
J Cardiovasc Pharmacol; 2007 Apr; 49(4):246-52. PubMed ID: 17438410
[TBL] [Abstract][Full Text] [Related]
11. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.
Vuilleumier N; Charbonney E; Fontao L; Alvarez M; Turck N; Sanchez JC; Burkhard PR; Mensi N; Righini M; Reber G; James R; Mach F; Chevrolet JC; Dayer JM; Frostegard J; Roux-Lombard P
Clin Sci (Lond); 2008 Jul; 115(1):25-33. PubMed ID: 18088236
[TBL] [Abstract][Full Text] [Related]
12. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
[TBL] [Abstract][Full Text] [Related]
13. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.
Prasad A; Clopton P; Ayers C; Khera A; de Lemos JA; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1213-1221. PubMed ID: 28473443
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease.
Ogasawara K; Mashiba S; Hashimoto H; Kojima S; Matsuno S; Takeya M; Uchida K; Yajima J
Clin Chim Acta; 2008 Nov; 397(1-2):42-7. PubMed ID: 18691566
[TBL] [Abstract][Full Text] [Related]
15. The complex link between oxidised low-density lipoprotein and unstable angina.
Niccoli G; Mongiardo R; Lanza GA; Ricco A; Burzotta F; Trani C; Mazzari MA; Liuzzo G; Lombardo A; Rebuzzi AG; Holvoet P; Crea F
J Cardiovasc Med (Hagerstown); 2007 May; 8(5):387-91. PubMed ID: 17443110
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
17. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease.
Boullier A; Hamon M; Walters-Laporte E; Martin-Nizart F; Mackereel R; Fruchart JC; Bertrand M; Duriez P
Clin Chim Acta; 1995 Jun; 238(1):1-10. PubMed ID: 7554289
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome.
Romero FI; Atsumi T; Tinahones FJ; Gómez-Zumaquero JM; Amengual O; Khamashta MA; Hughes GR
Arthritis Rheum; 1999 Dec; 42(12):2606-11. PubMed ID: 10616007
[TBL] [Abstract][Full Text] [Related]
19. Apolipoproteins as markers and managers of coronary risk.
Chan DC; Watts GF
QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.
Griffin ME; McInerney D; Fraser A; Johnson AH; Collins PB; Owens D; Tomkin GH
Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
